SEC Form 4 · accession 0001232524-17-000113
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce C Cozadd
Officer — Chairman & CEO · Director
Period of report
May 11, 2017
Accepted (ET)
May 12, 2017 · 7:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | May 11, 2017 | S | 12,073 | $153.1694 | D | 296,418 | D | |
| Ordinary SharesF2 | May 11, 2017 | S | 17,927 | $153.675 | D | 278,491 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.5200 to $153.5150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.5200 to $154.0400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.